Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tosylchloramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.59 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.59 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.53 |
| ▸ | NOD2 known ✓ | Q9HC29 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tosylchloramide SCHEMBL2441115 | 1.00 | GAA (0.61) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL3615720 | 0.98 | GAA (0.59) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL7225596 | 0.98 | GAA (0.59) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL6837208 | 0.98 | GAA (0.59) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL43534 | 0.98 | GAA (0.64) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL5854126 | 0.98 | GAA (0.64) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL29424143 | 0.98 | GAA (0.64) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL23547495 | 0.96 | GAA (0.57) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL2242608 | 0.95 | GAA (0.61) | GAASMN1; SMN2CA1CA2MMP1 | |
| Tosylchloramide SCHEMBL567565 | 0.95 | GAA (0.61) | GAASMN1; SMN2CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104529993-A | Preparation method of medicine micro-molecules containing unsaturated carbonyl | UNIV CHANGZHOU | 2015-04-22 | — | — | CN | claimed |
| CN-104524593-A | Method for releasing medicines by virtue of ester bond rupture | UNIV CHANGZHOU | 2015-04-22 | — | — | CN | claimed |
| CN-101830765-A | Method for synthesizing o-halohydrin | UNIV FUDAN | 2010-09-15 | — | — | CN | claimed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | claimed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | claimed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | claimed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | claimed |
| CN-122071464-A | Heterocyclic compound, pharmaceutical composition thereof and application thereof | 上海璎黎药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| EP-0647270-A1 | NOVEL MALIGNANT CELL TYPE MARKERS OF THE INTERIOR NUCLEAR MATRIX | MATRITECH, INC. (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5403837-A | Treating epilepsy, convulsions, schizophrenic and neurological disorders | RHONE POULENC RORER S.A. (FR) | 1995-04-04 | — | — | US | disclosed |
| WO-1995007271-A1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0642668-A1 | NUCLEAR MATRIX PROTEIN FLUID ASSAY | MATRITECH, INC. (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994000573-A1 | NOVEL MALIGNANT CELL TYPE MARKERS OF THE INTERIOR NUCLEAR MATRIX | MATRITECH, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993009437-A2 | NUCLEAR MATRIX PROTEIN FLUID ASSAY | MATRITECH, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| US-4113738-A | Conversion of N-tosylsulfoximides to sulfoximines | POLAROID CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | MMP1 3900/4885MMP8 4408/4885MMP13 4710/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | MMP1 4613/4885MMP8 4194/4885MMP13 4155/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | MMP1 710/4885MMP8 3087/4885MMP13 1924/4885 |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, CTNNB1 | MMP1 884/4885MMP8 953/4885MMP13 1310/4885 |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | OXER1, OXA1L, AOX1 | MMP1 4080/4885MMP8 3199/4885MMP13 3703/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | MMP1 4613/4885MMP8 4194/4885MMP13 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.